Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion

Neurocrine Biosciences (NASDAQ: NBIX) has announced a definitive agreement to acquire Soleno Therapeutics (NASDAQ: SLNO) for approximately $2.9 billion in cash, translating to $53 per share. This acquisition represents a 34% premium over Soleno's closing price prior to the announcement and a 51% premium to its 30-day volume-weighted average price. The deal is expected to close within 90 days, pending customary regulatory approvals.

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expands Rare Disease Portfolio With FDA-Approved VYKAT XR for Prader-Willi Syndrome 1BioSpaceUBS reiterates Neurocrine Bio stock rating on acquisition news By Investing.comSoleno Therapeutics (SLNO) Stock Soars 30% on $2.5B Neurocrine Acquisition NewsSoleno Therapeutics (SLNO) Stock Jumps 30% on Neurocrine $2.5B Buyout ReportNeurocrine (NBIX) to acquire soleno for $2.9 billionNeurocrine Biosciences: $2.9 Billion Acquisition Of Soleno Therapeutics To Expand Rare Disease PortfolioFiercePharma

The acquisition centers on Soleno's flagship product, Vykat XR (diazoxide choline), which is the first FDA-approved treatment for hyperphagia associated with Prader-Willi syndrome (PWS), a rare genetic disorder affecting about 10,000 patients in the U.S. Vykat XR generated $190 million in sales in 2025, including $92 million in the fourth quarter, indicating strong market adoption. Neurocrine CEO Kyle Gano emphasized that Vykat XR has the potential to become a "blockbuster" drug, with analysts projecting annual sales could exceed $1 billion by 2029.

ReutersNeurocrine Biosciences: $2.9 Billion Acquisition Of Soleno Therapeutics To Expand Rare Disease PortfolioFiercePharmaNeurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expands Rare Disease Portfolio With FDA-Approved VYKAT XR for Prader-Willi Syndrome 1BioSpaceNeurocrine (NBIX) to acquire soleno for $2.9 billionSoleno Therapeutics (SLNO) Stock Jumps 30% on Neurocrine $2.5B Buyout Report

Neurocrine's acquisition of Soleno is seen as a strategic move to enhance its portfolio in the rare disease and endocrinology sectors. The company currently markets two other rare-disease drugs, Ingrezza and Crenessity, which collectively generated $2.81 billion in revenue in 2025. Analysts at RBC Capital noted that this acquisition adds a "third leg" to Neurocrine's capabilities, potentially driving long-term revenue growth.

UBS reiterates Neurocrine Bio stock rating on acquisition news By Investing.com

The acquisition comes amid a wave of mergers and acquisitions in the biopharma sector, with other companies like Gilead Sciences and Merck also making significant purchases recently. However, Vykat XR faces competition from other biotech firms developing treatments for PWS. Notably, Aardvark Therapeutics recently paused a phase 3 trial for its candidate, and Acadia Pharmaceuticals abandoned its hyperphagia program after a phase 3 failure. Despite these setbacks for competitors, analysts remain cautious about Vykat XR's long-term prospects, citing potential challenges in expanding its market reach.

FiercePharma

Neurocrine's management expressed confidence in the acquisition. Gano stated, "What we’ve seen thus far across our diligence is all the profile aspects of a potential blockbuster in the making with Vykat XR." Meanwhile, Soleno's CEO Anish Bhatnagar remarked, "Neurocrine is the right strategic partner to expand the reach of Vykat XR in the Prader-Willi syndrome community."

Neurocrine Biosciences: $2.9 Billion Acquisition Of Soleno Therapeutics To Expand Rare Disease Portfolio

Despite the optimistic outlook, some analysts raised concerns about Vykat XR's initial launch performance, which has not met all expectations. UBS noted that while the acquisition diversifies Neurocrine's portfolio, the quality of the asset may be perceived as mixed, given Vykat XR's underperformance in its early market presence.

UBS reiterates Neurocrine Bio stock rating on acquisition news By Investing.com

Following the acquisition, Neurocrine aims to leverage its existing commercial infrastructure to enhance the adoption of Vykat XR. The company anticipates that the integration of Soleno will drive operational efficiencies and cost synergies. The deal is positioned to strengthen Neurocrine's leadership in rare disease treatments and support its long-term growth strategy.

FiercePharma

In summary, Neurocrine's acquisition of Soleno Therapeutics marks a significant expansion into the rare disease market, with Vykat XR poised to play a central role in the company's future growth trajectory.

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expands Rare Disease Portfolio With FDA-Approved VYKAT XR for Prader-Willi Syndrome 1